First in Class
METABOLIC INHIBITOR

New targeted therapy in Cancer “First in Class” & “Best in Class”
Inhibition of Protein Disulfide Isomerase
Oregon’s objective is to take this new drug candidate into clinical development.

PRESENTATION

OregonTherapeutics is developing XCE853 : Disruptive targeted therapy “First in class” & “Best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase.

OregonTherapeutics first objective is to bring XCE853 into Clinical Phase for the treatment of Cancer within 2 years. Based on the scientific rationale to exploit metabolic vulnerability of some cancers, the two priority indications are Ovarian Cancer and advanced Pancreatic Cancer.

Potential additional indications are: Liver, Prostate, Head & Neck and some Orphan Cancers.

PROJECT

ROAD MAP

TEAM

Marc-Henry PITTY – M.D. CEO

Marc-Henry PITTY has successfully created and developed several businesses in the healthcare sector. He graduated as a Medical Doctor from Paris University, also has a specialization in clinical Research and holds an MBA from ESSEC Business School in Paris

Denis CARNIATO – PhD. CTO

Dr Denis CARNIATO holds a PhD, from Pierre et Marie CURIE University (Paris) – with a specialty in Organic chemistry. Denis has 32 years experience in the Pharmaceutical industry with Senior R&D positions in medicinal chemistry programs & pre-clinical research. His has completed drug development programs in several therapeutic areas (Oncology, antifungal, women health, endocrinology, bone diseases & cardiovascular)

Grégoire PREVOST – PhD. CSO

Grégoire has extensive expertise in ONCOLOGY focusing on Research and Development projects, and has also pioneered Expert Drug Development Education programs in France. Grégoire brings with him 30 years of experience in Oncology research and development.

Patrick AMEIL -MBA. CFO

After graduating in business management from ESTP Paris and pursuing post graduate studies at ISG, Patrick AMEIL began his career as a management controller in several multinationals and then progressed to Financial Director of SMEs before finally, in 1990, buying a medium size industrial company.